Your browser is no longer supported. Please, upgrade your browser.
Settings
UTHR United Therapeutics Corporation daily Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E8.53 EPS (ttm)14.02 Insider Own0.10% Shs Outstand43.19M Perf Week2.70%
Market Cap5.17B Forward P/E13.08 EPS next Y9.15 Insider Trans-75.98% Shs Float42.84M Perf Month5.29%
Income613.90M PEG- EPS next Q2.55 Inst Own- Short Float8.93% Perf Quarter6.13%
Sales1.71B P/S3.02 EPS this Y-28.60% Inst Trans0.98% Short Ratio10.86 Perf Half Y-4.01%
Book/sh62.20 P/B1.92 EPS next Y-37.11% ROA17.30% Target Price125.27 Perf Year-12.63%
Cash/sh28.65 P/C4.17 EPS next 5Y-9.50% ROE22.10% 52W Range100.06 - 139.54 Perf YTD9.85%
Dividend- P/FCF12.49 EPS past 5Y13.80% ROI20.40% 52W High-14.27% Beta1.09
Dividend %- Quick Ratio4.00 Sales past 5Y13.50% Gross Margin87.20% 52W Low19.56% ATR2.32
Employees800 Current Ratio4.30 Sales Q/Q-7.40% Oper. Margin46.80% RSI (14)68.62 Volatility1.45% 2.09%
OptionableYes Debt/Eq0.00 EPS Q/Q-61.40% Profit Margin31.70% Rel Volume0.63 Prev Close118.54
ShortableYes LT Debt/Eq0.09 EarningsFeb 27 BMO Payout0.00% Avg Volume351.98K Price119.63
Recom- SMA203.02% SMA506.54% SMA2002.49% Volume220,116 Change0.92%
Oct-12-18Upgrade Standpoint Research Hold → Buy
Aug-08-18Downgrade Credit Suisse Neutral → Underperform
Apr-03-18Upgrade Credit Suisse Underperform → Neutral
Feb-22-18Reiterated Barclays Underweight $115 → $105
Jan-18-18Resumed Credit Suisse Underperform $118
Dec-27-17Reiterated Wedbush Outperform $213 → $232
Apr-27-17Reiterated Wedbush Outperform $229 → $213
Mar-30-17Initiated UBS Sell $112
Mar-16-17Initiated Credit Suisse Underperform
Mar-06-17Downgrade Jefferies Hold → Underperform
Feb-23-17Downgrade Ladenburg Thalmann Buy → Neutral
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Feb-13-19 10:31AM  Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for Zacks
10:00AM  Does United Therapeutics Corporations (NASDAQ:UTHR) CEO Salary Reflect Performance? Simply Wall St.
Jan-31-19 08:00PM  Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress PR Newswire
Jan-28-19 07:45AM  Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-25-19 07:38AM  The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug Benzinga
Jan-24-19 08:00PM  United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag PR Newswire
08:00PM  Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag PR Newswire
Jan-09-19 07:02PM  MoCo economic development officials plan satellite office in Boston American City Business Journals
Jan-08-19 09:54AM  Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares? Simply Wall St.
Dec-31-18 06:00AM  United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-17-18 10:11PM  United Therapeutics Corporation (UTHR): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-11-18 10:00AM  MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target Zacks Small Cap Research
Dec-07-18 02:22PM  Should You Be Excited About United Therapeutics Corporations (NASDAQ:UTHR) 20% Return On Equity? Simply Wall St.
Dec-03-18 06:46PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR PR Newswire
Nov-30-18 09:31AM  United Therapeutics (UTHR) Up 2% Since Last Earnings Report: Can It Continue? Zacks
Nov-29-18 04:30PM  Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma PR Newswire
Nov-27-18 05:00AM  Analysts: Why United Therapeutics has had a streak of licensing deals American City Business Journals
Nov-26-18 10:00AM  CORV: Topline Growth Accelerating Zacks Small Cap Research
Nov-23-18 07:25AM  Report: Exploring Fundamental Drivers Behind Harvard Bioscience, TTM Technologies, BSQUARE, United Therapeutics, KCAP Financial, and Gladstone Capital New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-21-18 11:21AM  Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal Zacks
Nov-17-18 08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Nov-16-18 09:11AM  Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22% Zacks
Nov-15-18 12:33PM  Why Arena Pharmaceuticals Stock Is Soaring Today InvestorPlace
11:05AM  Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today Motley Fool
07:33AM  United Therapeutics to develop, sell Arena Pharma's hypertension treatment Reuters
07:00AM  Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag PR Newswire
Nov-12-18 06:00AM  CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants PR Newswire
Nov-06-18 04:00PM  Correvio Reports Third Quarter 2018 Financial Results CNW Group
09:25AM  Edited Transcript of UTHR earnings conference call or presentation 31-Oct-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-01-18 11:14AM  United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips Zacks
06:00AM  Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors PR Newswire
Oct-31-18 02:46PM  United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript Motley Fool -9.63%
07:30AM  United Therapeutics (UTHR) Q3 Earnings and Revenues Beat Estimates Zacks
06:20AM  United Therapeutics: 3Q Earnings Snapshot Associated Press
06:00AM  United Therapeutics Corporation Reports Third Quarter 2018 Financial Results PR Newswire
Oct-24-18 06:00AM  United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018 PR Newswire -6.72%
Oct-23-18 03:20PM  An Intrinsic Calculation For United Therapeutics Corporation (NASDAQ:UTHR) Shows Its 45.03% Undervalued Simply Wall St.
Oct-22-18 04:00AM  CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants PR Newswire
Oct-17-18 10:32AM  United Therapeutics (UTHR) Q3 Earnings Preview: What's in the Cards? Zacks
Oct-16-18 05:22PM  Why MannKind Corp. Soared 16.4% Tuesday Motley Fool
06:00AM  United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement PR Newswire
06:00AM  United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement GlobeNewswire
Oct-15-18 11:38AM  AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally Zacks
Oct-11-18 09:51AM  Here's What Sent MannKind Corporation Soaring 66.4% in September Motley Fool
Oct-10-18 04:54PM  Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks
Oct-08-18 09:42AM  Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland Zacks
Oct-05-18 09:30AM  UTHR vs. NBIX: Which Stock Is the Better Value Option? Zacks
09:30AM  5 Stocks Trading Near 52-Week High With More Upside in Store Zacks
Oct-02-18 12:56PM  The exec makes how much? Here are the highest CEO-employee pay ratios in the D.C. area. American City Business Journals
Sep-27-18 02:25PM  MannKind Stock History Motley Fool
Sep-26-18 03:37PM  United Therapeutics, Martine Rothblatt's daughter sued for sexual harassment American City Business Journals
Sep-24-18 09:30AM  Should Value Investors Pick United Therapeutics (UTHR) Stock? Zacks
Sep-18-18 11:18AM  United Therapeutics In-Licenses Rights to IPF Candidate Zacks
06:00AM  United Therapeutics Corporation To Host Science Day 2018 PR Newswire
Sep-17-18 06:00AM  Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate PR Newswire
Sep-14-18 03:40PM  S Spotlight On United Therapeutics Corporations (NASDAQ:UTHR) Fundamentals Simply Wall St.
Sep-13-18 03:12PM  United Therapeutics makes another real estate buy American City Business Journals
Sep-08-18 07:50PM  Is MannKind Corporation Stock a Buy? Motley Fool
07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-07-18 06:00AM  RANKED: Best Places To Work - Extra-Large Companies American City Business Journals
Sep-06-18 03:02PM  A New Deal Moves MannKind Back From the Brink Motley Fool
08:52AM  The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals Zacks
Sep-05-18 04:56PM  New Development Partnership Could Pay Off Big for MannKind Stock InvestorPlace
11:12AM  MannKind Stock Up on Licensing Deal With United Therapeutics Zacks
09:39AM  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars Zacks
Sep-04-18 11:27AM  Why MannKind Stock Is Skyrocketing Today InvestorPlace
10:06AM  Why MannKind Corporation Stock Is Skyrocketing Today Motley Fool
09:19AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:54AM  United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery American City Business Journals
07:00AM  Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics CNW Group
Aug-31-18 11:51AM  United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue? Zacks
Aug-30-18 07:08AM  United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd. PR Newswire
Aug-28-18 03:45PM  CORV: US Brinavess Launch Now Reflected Zacks Small Cap Research
Aug-08-18 08:00PM  United Therapeutics Announces Settlement Of Patent Litigation With Watson Laboratories, Inc. Relating To Tyvaso PR Newswire
06:00AM  United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint PR Newswire
Aug-07-18 04:00PM  United Therapeutics Corporation To Present At 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-06-18 08:00AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and United Therapeutics ACCESSWIRE
Aug-02-18 11:40AM  United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip Zacks +5.64%
Aug-01-18 01:19PM  Edited Transcript of UTHR earnings conference call or presentation 1-Aug-18 1:00pm GMT Thomson Reuters StreetEvents -5.09%
08:16AM  United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates Zacks
06:11AM  United Therapeutics: 2Q Earnings Snapshot Associated Press
06:00AM  United Therapeutics Corporation Reports Second Quarter 2018 Financial Results PR Newswire
Jul-31-18 09:57AM  Medtronic Receives FDA Approval for Implantable System for Remodulin® to Treat Patients with Pulmonary Arterial Hypertension GlobeNewswire
06:00AM  United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin® PR Newswire
06:00AM  SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics GlobeNewswire
Jul-26-18 06:00AM  United Therapeutics Corporation To Report Second Quarter 2018 Financial Results Before The Market Opens On Wednesday, August 1, 2018 PR Newswire
Jul-20-18 06:00AM  HSR Act Waiting Period Terminated for United Therapeutics Acquisition of SteadyMed Ltd. GlobeNewswire
Jun-25-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Dr Pepper Snapple Group, United Therapeutics, Universal Health Realty Income Trust, Forestar Group, Schlumberger, and Thermo Fisher Scientific New Research Emphasizes Economic Growth GlobeNewswire
Jun-23-18 09:08AM  Is United Therapeutics Corporations (NASDAQ:UTHR) ROE Of 20.42% Sustainable? Simply Wall St.
Jun-20-18 03:46PM  How CEO Martine Rothblatt Turns Moonshots Into Earthshots Forbes
Jun-19-18 04:35PM  United Therapeutics CEO: Going public was my biggest mistake Yahoo Finance
Jun-12-18 01:30AM  United Therapeutics And XVIVO Perfusion Announce Collaboration To Reduce Organ Shortage Through Expansion Of Organ Evaluation Service PR Newswire
Jun-08-18 07:00AM  TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-06-18 06:18PM  Should You Buy United Therapeutics Corporation (NASDAQ:UTHR) At This PE Ratio? Simply Wall St.
04:03PM  Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln Reuters
Jun-01-18 09:34AM  United Therapeutics (UTHR) Up 3.9% Since Earnings Report: Can It Continue? Zacks
May-31-18 10:45AM  CORV: Cipher Transaction Done; Focus Back to Europe Zacks Small Cap Research
May-27-18 06:32AM  3 Healthcare Stocks That Are Undeniably Dirt Cheap Right Now Motley Fool
May-21-18 02:44PM  Maryland Commerce Department's Preakness guest list includes Amazon, Marriott execs American City Business Journals
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation has a licensing and collaboration agreement with MannKind Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension; and a licensing and commercialization agreement with Collplant for 3D bioprinting of solid-organ scaffolds for human transplants. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAHON PAUL AEVP & General CounselFeb 07Option Exercise65.806,000394,80041,613Feb 08 04:02 PM
CAUSEY CHRISTOPHERDirectorFeb 07Option Exercise63.9075047,9251,725Feb 08 04:03 PM
Thompson Tommy GDirectorFeb 05Sale117.0040046,8002,970Feb 05 04:28 PM
ROTHBLATT MARTINE AChairman & CEOJan 31Option Exercise52.657,054371,3937,194Feb 01 08:54 AM
ROTHBLATT MARTINE AChairman & CEOJan 31Sale115.307,054813,349140Feb 01 08:54 AM
ROTHBLATT MARTINE AChairman & CEOJan 30Option Exercise52.657,054371,3937,194Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 30Sale115.847,054817,160140Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 29Option Exercise52.657,054371,3937,194Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 29Sale115.707,054816,176140Jan 31 08:19 AM
ROTHBLATT MARTINE AChairman & CEOJan 28Option Exercise52.657,054371,3937,194Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 28Sale115.577,054815,238140Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 25Option Exercise52.657,054371,3937,194Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 25Sale115.167,054812,359140Jan 29 08:20 AM
ROTHBLATT MARTINE AChairman & CEOJan 24Option Exercise52.657,054371,3937,194Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 24Sale113.957,054803,780140Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 23Option Exercise52.657,054371,3937,194Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 23Sale112.947,054796,709140Jan 25 08:14 AM
ROTHBLATT MARTINE AChairman & CEOJan 22Option Exercise52.657,054371,3937,194Jan 23 08:28 AM
ROTHBLATT MARTINE AChairman & CEOJan 22Sale113.357,054799,591140Jan 23 08:28 AM
CAUSEY CHRISTOPHERDirectorJan 18Option Exercise63.9075047,9251,725Jan 22 05:01 PM
ROTHBLATT MARTINE AChairman & CEOJan 18Option Exercise52.657,054371,3937,194Jan 23 08:28 AM
ROTHBLATT MARTINE AChairman & CEOJan 18Sale115.157,054812,285140Jan 23 08:28 AM
ROTHBLATT MARTINE AChairman & CEOJan 17Option Exercise52.657,054371,3937,194Jan 17 06:39 PM
MAHON PAUL AEVP & General CounselJan 17Option Exercise65.806,000394,80041,613Jan 18 04:07 PM
ROTHBLATT MARTINE AChairman & CEOJan 17Sale113.797,054802,679140Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 16Option Exercise52.657,054371,3937,194Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 16Sale113.617,054801,423140Jan 17 06:39 PM
ROTHBLATT MARTINE AChairman & CEOJan 15Option Exercise52.657,054371,3937,194Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 15Sale114.867,054810,200140Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 14Option Exercise52.657,054371,3937,194Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 14Sale114.847,054810,056140Jan 15 04:47 PM
ROTHBLATT MARTINE AChairman & CEOJan 11Option Exercise52.657,054371,3937,194Jan 14 08:09 AM
ROTHBLATT MARTINE AChairman & CEOJan 11Sale113.597,054801,235140Jan 14 08:09 AM
ROTHBLATT MARTINE AChairman & CEOJan 10Option Exercise52.657,054371,3937,194Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 10Sale113.597,054801,235140Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 09Option Exercise52.657,054371,3937,194Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 09Sale113.437,054800,121140Jan 10 05:09 PM
ROTHBLATT MARTINE AChairman & CEOJan 08Option Exercise52.657,054371,3937,194Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 08Sale113.167,054798,220140Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 07Option Exercise52.657,055371,4467,195Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 07Sale113.407,055800,056140Jan 09 08:02 AM
ROTHBLATT MARTINE AChairman & CEOJan 04Option Exercise52.657,055371,4467,195Jan 07 06:38 PM
ROTHBLATT MARTINE AChairman & CEOJan 04Sale111.517,055786,719140Jan 07 06:38 PM
MAHON PAUL AEVP & General CounselJan 03Option Exercise65.806,000394,80041,613Jan 04 04:01 PM
SULLIVAN LOUIS WDirectorJan 02Option Exercise54.771,00054,7702,370Jan 03 04:02 PM
MAHON PAUL AEVP & General CounselDec 20Option Exercise65.806,000394,80041,613Dec 21 04:06 PM
Thompson Tommy GDirectorDec 11Option Exercise52.6590047,3854,270Dec 11 04:04 PM
MAHON PAUL AEVP & General CounselDec 06Option Exercise62.4810,000624,82042,613Dec 07 04:02 PM
SULLIVAN LOUIS WDirectorDec 03Option Exercise54.771,00054,7702,370Dec 04 04:04 PM
CAUSEY CHRISTOPHERDirectorNov 01Option Exercise54.7775041,0782,305Nov 02 04:08 PM
MAHON PAUL AEVP & General CounselNov 01Option Exercise61.066,000366,36041,613Nov 02 04:07 PM
MAHON PAUL AEVP & General CounselOct 18Option Exercise65.806,000394,80041,613Oct 19 04:03 PM
CAUSEY CHRISTOPHERDirectorOct 04Option Exercise54.7775041,0782,305Oct 09 08:21 AM
MAHON PAUL AEVP & General CounselOct 04Option Exercise61.066,000366,36041,613Oct 09 08:20 AM
SULLIVAN LOUIS WDirectorOct 01Option Exercise54.771,00054,7704,370Oct 02 04:11 PM
MAHON PAUL AEVP & General CounselSep 20Option Exercise61.066,000366,36041,613Sep 24 04:01 PM
CAUSEY CHRISTOPHERDirectorSep 10Sale119.0081096,3901,555Sep 10 04:05 PM
CAUSEY CHRISTOPHERDirectorSep 06Option Exercise54.7775041,0783,925Sep 07 04:15 PM
MAHON PAUL AEVP & General CounselSep 06Option Exercise61.066,000366,36041,613Sep 07 04:17 PM
CAUSEY CHRISTOPHERDirectorSep 06Sale118.0081095,5802,365Sep 07 04:15 PM
SULLIVAN LOUIS WDirectorSep 04Option Exercise54.771,00054,7704,370Sep 05 04:06 PM
MAHON PAUL AEVP & General CounselAug 16Option Exercise61.066,000366,36041,613Aug 17 04:06 PM
Giltner RichardDirectorAug 16Sale129.383,240419,1980Aug 17 04:08 PM
CAUSEY CHRISTOPHERDirectorAug 02Option Exercise54.7775041,0783,925Aug 03 04:03 PM
MAHON PAUL AEVP & General CounselAug 02Option Exercise61.066,000366,36041,613Aug 03 04:02 PM
SULLIVAN LOUIS WDirectorAug 01Option Exercise54.771,00054,7704,370Aug 02 04:05 PM
MAHON PAUL AEVP & General CounselJul 19Option Exercise61.066,000366,36041,613Jul 20 04:23 PM
PATUSKY CHRISTOPHERDirectorJul 06Option Exercise51.773,500181,1956,870Jul 09 04:02 PM
CAUSEY CHRISTOPHERDirectorJul 05Option Exercise54.7775041,0783,925Jul 06 04:06 PM
MAHON PAUL AEVP & General CounselJul 05Option Exercise61.066,000366,36041,613Jul 06 04:05 PM
SULLIVAN LOUIS WDirectorJul 02Option Exercise54.771,00054,7704,370Jul 05 04:13 PM
DWEK RAYMONDDirectorJun 29Sale113.073,240366,3530Jun 29 05:36 PM
Thompson Tommy GDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:31 PM
KURZWEIL RAYDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:25 PM
Giltner RichardDirectorJun 28Option Exercise0.003,24003,240Jun 28 07:21 PM
DWEK RAYMONDDirectorJun 28Option Exercise0.003,24003,240Jun 28 07:16 PM
PATUSKY CHRISTOPHERDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:11 PM
SULLIVAN LOUIS WDirectorJun 28Option Exercise0.001,62003,370Jun 28 07:05 PM
CAUSEY CHRISTOPHERDirectorJun 28Option Exercise0.001,62003,175Jun 28 06:59 PM
Olian Judy D.DirectorJun 28Option Exercise0.003,24006,130Jun 28 06:52 PM
MAHON PAUL AEVP & General CounselJun 21Option Exercise61.066,000366,36041,613Jun 25 05:03 PM
CAUSEY CHRISTOPHERDirectorJun 15Option Exercise54.772,250123,2333,805Jun 19 04:07 PM
Olian Judy D.DirectorJun 12Sale112.3860067,4252,890Jun 13 04:06 PM
MAHON PAUL AEVP & General CounselJun 07Option Exercise61.066,000366,36041,613Jun 08 04:24 PM
SULLIVAN LOUIS WDirectorJun 05Option Exercise51.7715,000776,55016,750Jun 06 04:01 PM
MAHON PAUL AEVP & General CounselMay 17Option Exercise61.066,000366,36041,613May 18 04:02 PM
MAHON PAUL AEVP & General CounselMay 03Option Exercise61.066,000366,36041,613May 04 04:16 PM
MAHON PAUL AEVP & General CounselApr 19Option Exercise61.066,000366,36041,613Apr 20 04:02 PM
ROTHBLATT MARTINE AChairman & CEOApr 09Option Exercise52.6521,5131,132,65921,653Apr 11 04:02 PM
ROTHBLATT MARTINE AChairman & CEOApr 09Sale110.8821,5132,385,368140Apr 11 04:02 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Option Exercise52.6521,5121,132,60721,652Apr 06 04:24 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Sale110.8821,5122,385,233140Apr 06 04:24 PM
ROTHBLATT MARTINE AChairman & CEOApr 05Option Exercise52.6521,5121,132,60721,652Apr 06 04:03 PM
MAHON PAUL AEVP & General CounselApr 05Option Exercise61.066,000366,36041,613Apr 06 04:05 PM
ROTHBLATT MARTINE AChairman & CEOApr 05Sale114.3021,5122,458,870140Apr 06 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 04Option Exercise52.6521,5121,132,60721,652Apr 06 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 04Sale114.9121,5122,471,995140Apr 06 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 03Option Exercise52.6521,5121,132,60721,652Apr 04 04:01 PM
ROTHBLATT MARTINE AChairman & CEOApr 03Sale114.5421,5122,463,912140Apr 04 04:01 PM
ROTHBLATT MARTINE AChairman & CEOApr 02Option Exercise52.6554728,800687Apr 04 04:01 PM